We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Defects in Newly Identified Molecular Pathway Lead to Parkinson's Disease

By LabMedica International staff writers
Posted on 16 Feb 2017
Print article
Image: Dopamine-making cells in a mouse brain (Photo courtesy of Sung-ung Kang, Johns Hopkins University).
Image: Dopamine-making cells in a mouse brain (Photo courtesy of Sung-ung Kang, Johns Hopkins University).
A molecular pathway has been traced that protects dopamine producing neurons and prevents Parkinson's disease, and this finding may pave the way for development of drugs to correct defects in this pathway in individuals who have the disease.

Previous work had demonstrated that mutations in the PINK1 (PTEN-induced putative kinase 1) gene and the parkin enzyme caused autosomal-recessive Parkinson’s disease through a common pathway involving mitochondrial quality control. Parkin inactivation was found to lead to accumulation of the PINK1 substrate, PARIS (Zinc Finger Protein 746, or parkin interacting substrate), which was shown to play an important role in dopamine cell loss.

In the current study, investigators at Johns Hopkins University found that PARIS linked PINK1 and parkin in a common pathway that regulated dopaminergic neuron survival. PINK1 interacted with and phosphorylated PARIS to control its ubiquitination and clearance for removal from the cell by parkin.

Results published in the January 24, 2016, online edition of the journal Cell Reports revealed that conditional knockdown of PINK1 in adult mouse brains led to a progressive loss of dopaminergic neurons in the substantia nigra region of the brain that was dependent on the resulting increase in levels of PARIS.

"Mutations in the genes for both Parkin and PINK1 have now been linked to Parkinson's disease," said senior author Dr. Ted Dawson, professor of neurology at Johns Hopkins University. "Parkin is a particularly big player that seems to be at fault in many inherited cases; it is also inactivated in sporadic cases of the disease. So a drug targeting PARIS could potentially help many patients."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.